Telluride Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Telluride Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$339K	Buy	+11,375	New	+$360K	0.29%	127

Other funds holding SRPT

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Telluride Asset Management's SRPT Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2014: 11,375 shares worth $339K. The stake represents 0.29% of the portfolio and ranks #127 among its holdings.

128 funds tracked by Wall St. Rank hold SRPT as of Q2 2014.

Telluride Asset Management held 11,375 shares of Sarepta Therapeutics worth $339K as of Q2 2014.
Sarepta Therapeutics was a new Telluride Asset Management position in Q2 2014.
Sarepta Therapeutics made up 0.29% of Telluride Asset Management's portfolio in Q2 2014, its #127 holding.
128 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.